PT  - JOURNAL ARTICLE
AU  - Francesca Bertolini
AU  - Andrea Elio Sprio
AU  - Elisa Riccardi
AU  - Andrea Baroso
AU  - Vitina Carriero
AU  - Fabio Luigi Massimo Ricciardolo
TI  - Features of FeNO-high asthma phenotype
AID  - 10.1183/13993003.congress-2021.PA3711
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3711
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3711.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3711.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: In asthma exhaled nitric oxide (FeNO) is considered a clinical-relevant biomarker for evaluating airway T2 inflammation. FeNO is related to severe and uncontrolled asthma and predicted exacerbations.Aims and objectives: The study aims to describe asthma phenotypes based on FeNO levels.Methods: 320 non-smoking asthmatics were retrospectively stratified according to FeNO values (FeNO-low, ≤25 ppb; FeNO-mid, 26-50 ppb; FeNO-high, >50 ppb). Clinical, functional and blood parameters in stable mild-to-severe asthmatics were extrapolated from the chart data.Results: FeNO-high showed higher prevalence in rhinitis (p <0.01 vs FeNO-low) and nasal polyposis (p <0.05 vs FeNO-mid, and p <0.01 vs FeNO-low), however they had a lower prevalence of GERD and arthropathy (p <0.05) than FeNO-low. The FeNO-high exhibited a greater airflow obstruction (TI%, p <0.05 vs FeNO-low), although displaying a better reversibility (∆FVC, p <0.05, and ∆FEV1, p <0.01) than FeNO-mid and FeNO-low. FeNO-high revealed a worsening in daily activity limitations (p <0.05 vs FeNO-mid). Concerning blood biomarkers, FeNO-high showed higher blood eosinophilia (p <0.001) and a higher percentage of patients with blood eosinophils >300cells/µL (p <0.001 vs FeNO-low and p <0.05 vs FeNO-mid). Finally, FeNO-high displayed a higher prevalence of highly-frequent exacerbators (≥3 asthma exacerbations per year, p <0.01, OR=3.2).Conclusions: The main features of FeNO-high asthma phenotype are elevated blood eosinophilia, greater reversible airflow obstruction and higher risk of frequent exacerbations associated with upper airways comorbidities. FeNO monitoring is a non-invasive test useful for patients who may also benefit from personalized therapeutic strategies.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3711.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).